Semiconductors
PrivateA genuine actinic-EUV monopoly wrapped in a cyclical order book and a still-unhealed governance scar — the moat is real, but at ~52x P/E near a fresh all-time high the market is paying monopoly rent for a business whose orders just fell 61% and whose top-3 customers are 77% of revenue; WATCHING for an entry, not a chase.
Research
The verdict
A genuine actinic-EUV monopoly wrapped in a cyclical order book and a still-unhealed governance scar — the moat is real, but at ~52x P/E near a fresh all-time high the market is paying monopoly rent for a business whose orders just fell 61% and whose top-3 customers are 77% of revenue; WATCHING for an entry, not a chase.
Lasertec makes the machines that check whether the most expensive stencils in human industry are perfect. It is a fab-lite / R&D-oriented ("fabless-style") designer and integrator of inspection and metrology systems for the semiconductor industry, founded 1960, headquartered in Yokohama, Japan, listed on the Tokyo Stock Exchange (Prime) under 6920 ``.
What it actually sells. The crown jewel is EUV photomask inspection — the tools that find killer defects on the masks (reticles) and mask blanks used in extreme-ultraviolet lithography at 7nm/5nm/3nm/2nm and below. Two franchises matter:
Business model = razor + very expensive razor + blades. ASPs run to ¥8–15bn per tool on the flagship EUV systems . On top of unit sales, an **installed-base service annuity** compounds: EUV inspection tools require ongoing maintenance, calibration and upgrades, so revenue accretes after delivery. That annuity is now visibly inflecting — **FY2025 service sales grew +48.3% YoY to ¥42.96bn** even as new-tool orders collapsed . This is the structurally attractive part of the story: as the fleet of shipped EUV tools grows, the recurring, higher-margin service base grows with it regardless of the order cycle.
Customers, suppliers, competitors (detail in Lenses 2–3): customers are the ~three companies on earth running leading-edge EUV fabs — TSMC, Samsung, Intel — plus the mask-blank/photomask supply chain (Hoya, AGC, Toppan, DNP). Its closest competitor is KLA; Zeiss plays in adjacent actinic mask imaging (AIMS EUV).
Contract structure / payment terms. Big-ticket, long-lead capital equipment (multi-quarter build cycles), typically with customer advances/progress payments and revenue recognised on delivery/acceptance — the exact recognition mechanics are the crux of the Lens 10 forensic discussion and were the core of the 2024 short thesis. Backlog is the visibility instrument: ~¥316bn at FY2025 year-end ``, i.e. well over one year of revenue booked.
Lasertec sits at a single, narrow chokepoint inside the broader EUV value chain. Map it end to end, named:
Upstream inputs into Lasertec's tools → Lasertec → the customer that needs the tool → the end product:
Chokepoints / single-source dependencies:
This lens is web-derived; the specific per-supplier contract terms are not disclosed and are n/a.
Lasertec has one of the cleaner technology-monopoly moats in hardware — but it is a narrow moat with a concentrated customer set, which is exactly the tension the whole thesis turns on.
The moat, ranked by durability:
. Near-**100% share in actinic**, ~**90%+ in EUV mask inspection** overall .Bargaining power — who needs whom more?
Where the moat is thinner than bulls claim: it is a single-product-line monopoly on a single, cyclical, customer-concentrated demand driver. That is a very different risk profile from, say, ASML's monopoly (which every leading-edge chip on earth requires). Lasertec's monopoly is real but its demand is neither diversified nor non-cyclical.
No segments.csv data exists on the shelf — every figure ``; treat as approximate and reconcile against the FY2025 tanshin on next ingest.
By product line (FY2025, year ended June 2025):
Read on the trend: the mix is quietly shifting toward service, which is the healthiest possible direction (higher-margin, recurring, order-cycle-insensitive). The equipment line's +11.7% is revenue (recognised backlog burning down), which masks the real leading indicator — orders fell 61.4% YoY to ¥105.2bn with ACTIS cancellations in Q4 — see Lens 5/8. Revenue is a rear-view mirror here; the order book is the windshield, and the windshield turned ugly in FY2025 even as the P&L printed records.
By geography (FY2025): the United States was the largest region, followed by Taiwan and South Korea ``. The US-first mix is notable — it reflects Intel's leading-edge push and US-based mask/fab activity, not just the TSMC/Samsung Asia base. Precise geographic percentages are n/a (behind Statista paywall).
Fiscal year ends June 30. FY2026 = the year ending June 2026, so as of July 2026 the last full print is Q2 FY2026 (Oct–Dec 2025), reported ~2 Feb 2026; H2 FY2026 (through June 2026) has likely just closed but full-year FY2026 actuals are not yet in the shelf.
Q2 FY2026 (reported Feb 2026):
Q1 FY2026 (reported ~31 Oct 2025), for context:
FY2026 full-year guidance (as revised):
Margins. Operating margin sits in the 45–49% band with ROE ~44–48% `` — extraordinary for capital equipment, and the empirical core of the bull case and the short case (bulls: monopoly rent; shorts: too good to be true, hence "fraud"). Both can't be right; the Special Investigation Committee (Lens 10) sided with "it's real."
Balance-sheet flags. FY2025 (June 2025): total assets ¥329.6bn, shareholders' equity ¥207.9bn, net income attributable to owners ¥84.65bn . Equity ratio ~63% — conservative, effectively **net cash** (a separately-sourced "¥30.66bn cash / ¥17.56bn OCF" figure is inconsistent with group scale and is flagged unreliable / partial — n/a — not reliably sourced; reconcile on ingest). The forensic tension is not leverage — it's inventory and revenue-recognition timing (Lens 10).
Market reaction: the Feb 2026 outlook-day reaction was a ~10% drop — "raised outlook less than investors anticipated in the face of an AI-related surge in spending" ``. Classic expectations-vs-reality gap on a high-multiple name.
Unusual vs. its own history: the orders/revenue divergence is the flag — FY2025 delivered record revenue and profit while orders fell 61% and backlog fell 32%. A print that looks like a peak because it is one on the recognised-revenue line, while the leading indicator already rolled.
No transcripts/ on the shelf; sentiment reconstructed from IR presentation scripts/FAQs ``.
Recurring phrases: "monopoly / only actinic," "installed base / service growth," "multi-year backlog," "High-NA readiness (A200HiT)." Things they stopped saying: the confident double-digit dividend growth guidance — FY2026 dividend is now guided flat at ¥329 vs prior double-digit hikes ``, a quiet tell that management sees the near term as a plateau, not a launchpad.
Peer set: EUV/inspection & leading-edge WFE. All multiples `` with source; where I cannot source cleanly, n/a. No multiple is fabricated.
| Company | Ticker | Mkt cap (USD) | P/E (TTM) | EV/EBITDA | P/S | ROE | Notes |
|---|---|---|---|---|---|---|---|
| Lasertec | 6920.T | ~$27–34bn (¥~5tn) `` | ~52x `` | ~35x `` | ~18x `` | ~44–48% `` | Actinic-EUV monopoly; order-cycle exposed |
| KLA | KLAC | n/a | ~30x fwd `` | ~24–30x `` | n/a | n/a | Process-control leader; e-beam mask inspection; diversified |
| Applied Materials | AMAT | n/a | ~22x fwd `` | ~17x `` | n/a | n/a | Broadest WFE; least premium |
| ASML | ASML | n/a | ~45x fwd `` | ~34.5x `` | n/a | n/a | The true EUV monopoly; Lasertec's roadmap dependency |
| Zeiss SMT | (Carl Zeiss AG / private-ish) | n/a | n/a | n/a | n/a | n/a | Optics + AIMS EUV actinic imaging |
Read. Lasertec at ~52x P/E and ~35x EV/EBITDA is priced at or above ASML — the semiconductor industry's only indispensable-to-every-chip monopoly — and at a large premium to KLA (~30x fwd), its nearest functional peer, and to AMAT (~22x). The premium is partly earned by best-in-class ~45–49% operating margin and ~44–48% ROE. But the market is capitalising Lasertec's monopoly rent as if its demand were as durable as ASML's, when in fact its demand is (a) more cyclical, (b) far more customer-concentrated (77% top-3), and (c) currently in an order down-cycle (−61% orders). That is the valuation crux: a monopoly multiple on a non-monopoly demand profile.
The tape reveals what the market actually reacts to for this name. Pattern: (1) EUV-capex/AI-cycle sentiment, (2) order/guidance surprises, and (3) the governance scar — not day-to-day product news.
What the market reacts to: order momentum and the AI/EUV-capex narrative, amplified by a high multiple (so small expectation gaps → big moves), with a persistent governance-risk discount that lingers post-Scorpion. It does not meaningfully react to incremental product launches unless they change the demand math (High-NA).
. A **long, stable, ~15+ year tenure** through the entire EUV build-out — Lasertec went from a niche microscope/inspection maker to a ¥5tn actinic-EUV monopoly on his watch, which is a genuinely elite value-creation record *by outcome*. (Note: some sources list a separate CEO title/appointment in 2023 — Japanese board structures split "President/Representative Director" from "CEO"; Okabayashi is consistently the operating principal. Reconcile exact titles on ingest — , mild ambiguity.)n/a. Japanese executive equity stakes are typically modest vs. US founder-CEOs; specific insider holdings not sourced. This is a gap to close before sizing any position.. Low capex (fab-lite: ~¥2.4bn) → **very high ROE (~44–48%)** and high FCF conversion. No value-destroying M&A on record. The one *soft* flag: FY2026 dividend held **flat at ¥329** after years of double-digit growth — a signal of near-term caution, not misallocation.Forensic lens. No filings on the shelf → this is built from web-sourced financials + the public record of the 2024 short thesis and the investigation. Every figure ; the primary tanshin should be ingested to convert these to .
The structural forensic question for Lasertec is timing, not solvency. It is net-cash with a 63% equity ratio, so there is no leverage/going-concern risk. The risk lives in long-lead capital-equipment revenue recognition and inventory/working-capital build — precisely where the short thesis aimed.
. The **Special Investigation Committee (Jul 2024) found no evidence** of revenue-recognition or inventory-accounting irregularities . Net: the specific fraud allegation is unproven and formally rebutted, but the sensitivity of reported profit to recognition timing is real and inherent to the model — a bear should stress-test it.n/a (not disclosed in the aggregated web data; the tanshin has them). This is the single highest-value gap in this dossier — do not opine on the QoE without the actual inventory and contract-liability lines from the FY2025/H1-FY2026 tanshin.n/a — not reliably sourced — a real QoE read requires the primary statement.Regulatory findings (required sub-section):
regulatory/regulatory-findings.md (generated 2026-07-06, total_sec_findings: 0): no EDGAR LR/AAER search is applicable ``."Lasertec" (FTC OR DOJ OR FDA OR settlement OR fine OR penalty) enforcement surfaces no government enforcement action. The only "official" scrutiny stemming from the Scorpion episode is US plaintiff-side shareholder-investigation solicitations (Bronstein Gewirtz & Grossman; Pomerantz) announced June 2024 — these are law-firm investigation notices targeting ADR holders, not regulatory findings and not filed suits with adverse outcomes ``. No Japanese FSA/SESC enforcement or restatement on record.Bottom-up from FY2025 actuals + FY2026 guidance. Fiscal years end June. Every input or; outputs with arithmetic. Share count for EPS: not cleanly sourced → I project **operating income / net income levels** and give EPS only as a labelled derivation. Shares outstanding ≈ **90–91m**.
Anchors:
Three-year net-income path (FY2026E → FY2028E) — net income attributable, ¥bn:
| Year | Bear | Base | Bull | Key assumption |
|---|---|---|---|---|
| FY2026E | ~72 | ~78 | ~82 | Guided OP ¥100bn → NI ≈ ¥100bn × ~0.7 tax + non-op ≈ ¥72–82bn `` |
| FY2027E | ~68 (orders stay soft; no High-NA pull-through yet) | ~92 (orders trough behind us, service +40%, early High-NA masks) | ~115 (order re-acceleration + High-NA inspection demand front-runs) | Orders inflection is the swing; base = mild sales recovery to ~¥260bn at ~47% OP |
| FY2028E | ~78 | ~112 (High-NA mass-production year: mask complexity + service compounding) | ~150 (full High-NA actinic demand + share held at ~100%) | High-NA is the up-leg; bear = TSMC High-NA deferral bites |
**EPS derivation (base, ):** FY2026E NI ~¥78bn ÷ ~90.9m sh ≈ **~¥858 EPS**; FY2028E base ~¥112bn ÷ ~90.9m ≈ **~¥1,232 EPS** . At ~¥55,000, FY2026E base P/E ≈ ~64x; FY2028E base P/E ≈ ~45x `` — i.e. even on a constructive 2-year-out base case, the multiple only compresses to today's ASML level, and only if High-NA delivers on schedule.
The base call is fundamentally a bet on the High-NA timing — orders re-accelerating into 2027–28 and Lasertec holding ~100% actinic share into that wave. If that timing slips (TSMC has said it will not adopt High-NA for its 1.4nm node ``, deferring one large buyer), the bear path dominates.
(forecast.ts create skipped — unattended --watchlist run per SKILL; log a Brier forecast only on a committed base case in an interactive /thesis pass. Suggested forecast to log later: "6920.T FY2027 net income attributable ≥ ¥90bn," p≈0.5, resolves 2027-08-15.)
Bull case. Lasertec owns a true, ~100%-share actinic-EUV inspection monopoly at a physical chokepoint that every leading-edge EUV mask must pass through — and that necessity intensifies as the industry moves to 2nm, then High-NA (thinner films, tighter defect budgets make actinic inspection more, not less, essential). It converts that monopoly into ~45–49% operating margins and ~44–48% ROE on a fab-lite, net-cash, low-capex model that gushes FCF and returns it (dividend + buyback). Underneath the cyclical equipment line, a service annuity compounding ~+48%/yr is building an order-cycle-insensitive earnings floor. The AI-infrastructure build-out is the secular tailwind; the ASML High-NA ramp (2027–28) is a second demand wave the market is only beginning to price. And the biggest tail risk — the fraud allegation — was formally investigated and dismissed, so the 2024 derate was, in hindsight, a gift.
Bear case (2–3 things that could permanently impair or de-rate it).
Pre-mortem (18 months out, thesis broke — what happened?): Orders failed to re-accelerate through 2026–27 because (a) TSMC's High-NA deferral + a broader AI-capex digestion pushed the mask-inspection wave right, and (b) a competitor (KLA e-beam, or a Zeiss/JV actinic effort) qualified an alternative on the High-NA node, cracking the 100% share narrative at exactly the moment the multiple needed it to hold. The stock de-rated from ~52x toward KLA's ~30x on a lower earnings base → a 40–50% drawdown, and a fresh disclosure question reignited the QoE overhang.
Are multiples too high? On today's earnings, yes — a monopoly-plus multiple that only looks reasonable if you underwrite the FY2028 High-NA up-leg with confidence. The margin of safety is thin.
Contrarian view (what the market refuses to see). The bull consensus treats Lasertec's monopoly as ASML-like (indispensable, durable, deserves the premium). The contrarian read: the monopoly is real but the demand is not ASML-like — it is cyclical, hyper-concentrated, and its flagship growth catalyst (High-NA) just lost its biggest customer (TSMC) at the leading node. The market is paying for monopoly durability it is actually only getting on share, not on volume cadence. The other contrarian point cuts bullish: the service annuity is under-appreciated — if you value the recurring installed-base stream separately from the lumpy equipment line, the "quality" of the earnings is higher than the order-cycle bears think. Both contrarian reads point to the same trade: own the service-annuity compounder at a cyclical-trough order print and a de-rated multiple — not at a fresh all-time high on a guidance-raise-that-disappointed.
Channeling the actual short case — Scorpion Capital, June 2024 — plus the structural bear.
Best analog franchise on Earth, mid-cycle, fully priced — the FCF-inflection thesis is now consensus at ~40x forward and above Street targets; you're buying quality at a cyclical-optimism peak, with China share-loss the under-priced tail. WATCHING, not chasing.
The pure-play picks-and-shovels winner of AI-chip test, printing a vertical Q1'26 (+87%, $2.53 EPS) — but the stock fell ~14% on it because Q2 guidance steps DOWN sequentially and a ~54x P/E prices permanent acceleration; great business, demanding price, cyclical tape. NEUTRAL/WATCHING into the next print.
Best-in-class EDA franchise temporarily wearing an Ansys-debt-and-amortization disguise — the GAAP "collapse" is accounting, not the business; the real risk is paying ~35x forward for a name whose Design-IP leg is structurally cracked and whose synergy math doesn't pay until FY2028.